Sumatriptanaproxen sodium combination versus its components administered concomitantly for the acute treatment of migraine: a pragmatic crossover open-label outcomes study

摘要

Objective:Efficacy and tolerability profiles of Treximet [sumatriptanaproxen sodium combination tablet (SNC)] have been established in clinical trials but have to date been virtually unstudied in pragmatic research. The primary objective of this study was to compare the overall satisfaction of SNC to its monotherapy components, S/N [one 100 mg Imitrex tablet (S) and two Aleve (naproxen sodium) 220 mg tablets, total dose 440 mg (N)] administered concomitantly using the Patient Perception of Migraine Questionnaire –Revised (PPMQ-R).